Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | TNF | P01375 | 1/20 | 0.58 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.52 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.52 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.52 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31305897 | 1.00 | RAB9A (0.60) | RAB9AL3MBTL1NPC1TNFNOD1 | |
| Hydrochloric Acid SCHEMBL31305933 | 0.99 | RAB9A (0.59) | RAB9AL3MBTL1NPC1TNFNOD1 | |
| Hydrochloric Acid SCHEMBL1290649 | 0.99 | RAB9A (0.59) | RAB9AL3MBTL1NPC1TNFNOD1 | |
| SCHEMBL31305909 | 0.90 | RAB9A (0.58) | RAB9AL3MBTL1NPC1TNFNOD1 | |
| SCHEMBL1290567 | 0.90 | RAB9A (0.58) | RAB9AL3MBTL1NPC1TNFNOD1 | |
| SCHEMBL1291031 | 0.89 | RAB9A (0.57) | RAB9AL3MBTL1NPC1TNFNOD1 | |
| SCHEMBL31305895 | 0.89 | RAB9A (0.57) | RAB9AL3MBTL1NPC1TNFNOD1 | |
| Hydrochloric Acid SCHEMBL1291005 | 0.89 | RAB9A (0.57) | RAB9AL3MBTL1NPC1TNFNOD1 | |
| Hydrochloric Acid SCHEMBL1290670 | 0.88 | RAB9A (0.56) | RAB9AL3MBTL1NPC1TNFNOD1 | |
| SCHEMBL1290937 | 0.87 | RAB9A (0.51) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250134872-A1 | ANTITUMOR COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-05-01 | — | — | US | claimed |
| US-20240417376-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-12-19 | — | — | US | claimed |
| US-20230139808-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-05-04 | — | — | US | claimed |
| US-20220202794-A1 | ANTITUMOR COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-06-30 | — | — | US | claimed |
| CN-113597309-A | Antitumor composition | 大塚制药株式会社 | 2021-11-02 | — | — | CN | claimed |
| US-20210017134-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-01-21 | — | — | US | claimed |
| US-20200031773-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-01-30 | — | — | US | claimed |
| US-20180265471-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-09-20 | — | — | US | claimed |
| US-20170298023-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMA CO LTD (JP) | 2017-10-19 | — | — | US | claimed |
| US-20150105432-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. | 2015-04-16 | — | — | US | claimed |
| US-8946437-B2 | 4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | claimed |
| EP-2624833-B1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMA CO LTD (JP) | 2014-12-10 | — | — | EP | claimed |
| US-20130267565-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN -3- YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-10 | — | — | US | claimed |
| US-20250134872-A1 | ANTITUMOR COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-05-01 | — | — | US | disclosed |
| US-12220410-B2 | Antitumor composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-02-11 | — | — | US | disclosed |
| US-20240417376-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-12-19 | — | — | US | disclosed |
| EP-2624833-B1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMA CO LTD (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-20130267565-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN -3- YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-10 | — | — | US | disclosed |
| EP-2624833-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN- 3 - YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | Otsuka Pharmaceutical Co., Ltd. (JP) | 2013-08-14 | — | — | EP | disclosed |
| WO-2012046825-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN- 3 - YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105432-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, IDH2, GLS2 | RAB9A 1655/4885L3MBTL1 382/4885NPC1 1910/4885 |
| US-20250134872-A1 | ANTITUMOR COMPOSITION | MCL1, BAK1, BCL2 | RAB9A 2856/4885L3MBTL1 1635/4885NPC1 4327/4885 |
| US-20230139808-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, IDH2, MDH2 | RAB9A 1752/4885L3MBTL1 394/4885NPC1 1700/4885 |
| US-20130267565-A1 | 4- (METHYLAMINOPHENOXY) PYRDIN -3- YL - BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, MDH2, IDH2 | RAB9A 1673/4885L3MBTL1 363/4885NPC1 1899/4885 |
| US-20180265471-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, GLS2, IDH2 | RAB9A 1652/4885L3MBTL1 382/4885NPC1 1900/4885 |
| US-20240417376-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, GLS2, IDH2 | RAB9A 1652/4885L3MBTL1 382/4885NPC1 1900/4885 |
| US-20170298023-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | IDH2, MDH2, HCCS | RAB9A 1651/4885L3MBTL1 348/4885NPC1 1844/4885 |
| US-20200031773-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, GLS2, IDH2 | RAB9A 1652/4885L3MBTL1 382/4885NPC1 1900/4885 |
| US-20220202794-A1 | ANTITUMOR COMPOSITION | MCL1, BAK1, BCL2 | RAB9A 2856/4885L3MBTL1 1635/4885NPC1 4327/4885 |
| US-20210017134-A1 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | HCCS, GLS2, IDH2 | RAB9A 1652/4885L3MBTL1 382/4885NPC1 1900/4885 |
| US-12220410-B2 | Antitumor composition | MCL1, BAK1, BCL2 | RAB9A 2856/4885L3MBTL1 1635/4885NPC1 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.